ICT-01 is under clinical development by ImCheck Therapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase II drugs for Diffuse Large B-Cell Lymphoma have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ICT-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ICT-01 overview

ICT-01 is under development for the treatment of relapsed and refractory solid tumors including bladder cancer, breast cancer, colon cancer, gastric cancer, melanoma, ovarian cancer, prostate cancer, metastatic colorectal cancer, metastatic ovarian cancer, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer and relapsed and refractory hematologic malignancies including acute myeloid leukemia, acute lymphocytic leukemia, Diffuse large B cell lymphoma, pancreatic ductal adenocarcinoma and follicular lymphoma. The drug candidate acts by targeting butyrophilin subfamily 3 (BTN3) and activating gamma delta T cells.

ImCheck Therapeutics overview

ImCheck Therapeutics is an independent biotechnology company that develops drugs for cancer and auto-immune disorders. The company is developing two first-in-class immunomodulator antibodies that are effective against adaptive and innate immunity to treat cancer and other immune related diseases. It works in collaboration with institutions and academics to develop precision and personalized medicines. The company is a spin-off from Marseille’s Institut Paoli-Calmettes. ImCheck Therapeutics is headquartered in Marseille, Provence – Alpes- Cote d’Azur, France.

For a complete picture of ICT-01’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.